Wedbush Downgrades Chinook Therapeutics to Neutral From Outperform as Sale to Novartis Draws Closer; Keeps $42 Price Target
Wedbush Downgrades Chinook Therapeutics to Neutral From Outperform as Sale to Novartis Draws Closer; Keeps $42 Price Target
随着对诺华的出售越来越近，Wedbush 将Chinook Therapeutics的评级从跑赢大盘下调至中性；维持42美元的目标股价
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册